Incidence of endophthalmitis following intravitreal bevacizumab injection at a tertiary care hospital in eastern province of Saudi Arabia

The aim of this communication is to report the incidence of endophthalmitis following the use of intravitreal Bevacizumab [IVB] at a tertiary care hospital in the Eastern province of Saudi Arabia. A total of 2769 intravitreal Bevacizumab injections were carried out between January 2009 and April 2014. During this period, one case of endophthalmitis following IVB injection occurred. The overall incidence of clinical endophthalmitis was 0.036% [1/2769; 95% confidence interval: 0.0001-0.002%]. This compares favorably with studies reported from other parts of the world